At Spark® Therapeutics, we are leveraging our unique technical and R&D expertise as we strive to bring gene therapies to patients. One of our areas of research is hemophilia A, an inherited bleeding disorder caused by mutations in the F8 gene that encodes coagulation factor VIII. We recognize the essential need to understand and gain important perspectives from patients, caregivers and leaders in the community. Spark® Therapeutics is a member of the Roche Group.